BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2856207)

  • 1. Vaccine induced HSV 1 antibodies fail to correlate with protection against HSV 2 in guinea pigs.
    Welch MJ; Ridgeway PH; Phillpotts RJ
    FEMS Microbiol Immunol; 1988 Dec; 1(3):157-62. PubMed ID: 2856207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine-induced antibodies to herpes simplex virus glycoprotein D epitopes involved in virus entry and cell-to-cell spread correlate with protection against genital disease in guinea pigs.
    Hook LM; Cairns TM; Awasthi S; Brooks BD; Ditto NT; Eisenberg RJ; Cohen GH; Friedman HM
    PLoS Pathog; 2018 May; 14(5):e1007095. PubMed ID: 29791513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of HSV-1 ISCOM vaccine in the guinea-pig model of HSV-2 infection.
    Erturk M; Phillpotts RJ; Welch MJ; Jennings R
    Vaccine; 1991 Oct; 9(10):728-34. PubMed ID: 1661978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D.
    Berman PW; Gregory T; Crase D; Lasky LA
    Science; 1985 Mar; 227(4693):1490-2. PubMed ID: 2983428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody reactivity with Skinner HSV vaccine.
    Muniu EM; Durham J; Shariff D; Hartley CE; Fuller A; Melling J; Wiblin C; Wilkins G; Buchan A; Skinner GR
    Med Microbiol Immunol; 1987; 176(6):315-27. PubMed ID: 2828898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes.
    Stanberry LR; Bernstein DI; Burke RL; Pachl C; Myers MG
    J Infect Dis; 1987 May; 155(5):914-20. PubMed ID: 3031173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of herpes simplex virus (HSV) type 1 ISCOMS 703 vaccine for prophylactic and therapeutic treatment of primary and recurrent HSV-2 infection in guinea pigs.
    Simms JR; Heath AW; Jennings R
    J Infect Dis; 2000 Apr; 181(4):1240-8. PubMed ID: 10762560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines.
    Weinberg A; Merigan TC
    J Immunol; 1988 Jan; 140(1):294-9. PubMed ID: 2826591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection and serum antibody responses in guinea-pigs and mice immunized with HSV-1 antigen preparations obtained using different detergents.
    Ertürk M; Welch MJ; Phillpotts RJ; Jennings R
    Vaccine; 1989 Oct; 7(5):431-6. PubMed ID: 2554607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Herpes simplex virus genital infection of the female guinea pig as a model for the evaluation of an experimental vaccine.
    Thornton B; Baskerville A; Bailey NE; Melling JM; Hambleton P
    Vaccine; 1984 Jun; 2(2):141-8. PubMed ID: 6099646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and efficacy of antiherpes type 1 and 2 subunit vaccines.
    Kavaklova L; Dundarov S; Andonov P; Bakalov B; Dundarova D; Brodvarova I
    Acta Virol; 1986 Sep; 30(5):402-10. PubMed ID: 2878588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of a herpes simplex subunit vaccine.
    Cappel R; Sprecher S; De Cuyper F; De Braekeleer J
    J Med Virol; 1985 Jun; 16(2):137-45. PubMed ID: 2989419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs.
    Bernard MC; Barban V; Pradezynski F; de Montfort A; Ryall R; Caillet C; Londono-Hayes P
    PLoS One; 2015; 10(4):e0121518. PubMed ID: 25837802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
    Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
    J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune response to a DNA free herpes simplex vaccine in man.
    Cappel R; Sprecher S; Rickaert F; de Cuyper F
    Arch Virol; 1982; 73(1):61-7. PubMed ID: 6289778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Native herpes simplex virus glycoprotein D vaccine: immunogenicity and protection in animal models.
    Mishkin EM; Fahey JR; Kino Y; Klein RJ; Abramovitz AS; Mento SJ
    Vaccine; 1991 Mar; 9(3):147-53. PubMed ID: 1645898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement-requiring neutralizing antibody in guinea pigs with primary and recurrent genital herpes.
    Zheng ZM; Hsiung GD
    Proc Soc Exp Biol Med; 1984 Nov; 177(2):332-6. PubMed ID: 6091148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody to herpes simplex virus (HSV) ICP-35 proteins after HSV challenge of animals immunized with HSV subunit vaccines.
    Bernstein DI; Stanberry LR; Kappes JC; Burke RL; Myers MG
    J Infect Dis; 1988 Jun; 157(6):1178-86. PubMed ID: 2836519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A test for the relative potency of herpes simplex virus vaccines based upon the female guinea-pig model of HSV 2 genital infection.
    Phillpotts RJ; Welch MJ; Ridgeway PH; Walkland AC; Melling J
    J Biol Stand; 1988 Apr; 16(2):109-18. PubMed ID: 2836425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine.
    Kohl S; Charlebois ED; Sigouroudinia M; Goldbeck C; Hartog K; Sekulovich RE; Langenberg AG; Burke RL
    J Infect Dis; 2000 Jan; 181(1):335-9. PubMed ID: 10608784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.